The Hottest Topics and Technologies in Interventional Cardiology at TCT 2013
By Dave Fornell, DAIC editor
The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting brought many new insights about the latest cardiovascular technologies and treatment techniques. Among the hottest topics were transcatheter heart valve repairs, renal denervation to treat drug resistant hypertension, left atrial appendage (LAA) occluders to prevent stroke and eliminate warfarin therapy in atrial fibrillation patients, bifurcation stenting trials and techniques, new insights on anti-clotting agents, increasing use of ultrasound and intravascular imaging, new technologies for FFR lesion assessments, and the latest stent trial data.
I offer my editor’s choice for the most innovative new technologies presented in sessions and on the show floor in a video format.
For a video of the top meeting highlights, Herb Aronow, M.D., offers his views on some of the most interesting topics discussed in sessions.
The most exciting interventional device to enter the U.S. market a couple days prior to TCT was Abbott's MitraClip. We conducted a video interview with the lead author of the MitraClip FDA pivotal trial at TCT.
Here is a summary of some of the top news from TCT. You can click on any item to read the full story.
In addition to these news items, listed below are more top trial summaries and new product releases.
More like this
- MitraClip Demonstrates Positive Results for Patients With Degenerative Mitral Regurgitation
- MitraClip Demonstrates Positive Results for High-Risk, Degenerative MR Patients
- Editor’s Choice of Most Innovative Cardiovascular Technology at TCT 2013
- Ongoing Progress of MitraClip Therapy Highlighted at TCT 2009
- Abbott Presents New Data for Key Vascular Products at TCT 2011